lisinopril + placebo

Lisinopril + placebo refers to a specific treatment arm used in GlaxoSmithKline's Phase 3 clinical trial (NCT00624065, COR111096) for the treatment of Stage 1 or 2 essential hypertension. In this arm, patients received lisinopril, a small molecule angiotensin-converting enzyme (ACE) inhibitor, along with a placebo designed to match the appearance of carvedilol CR. This setup allowed for a double-blind comparison between lisinopril monotherapy and the combination of carvedilol CR plus lisinopril. Lisinopril works by inhibiting the conversion of angiotensin I to angiotensin II, which reduces systemic vascular resistance and blood pressure without increasing heart rate. This treatment arm was used to establish the baseline efficacy of lisinopril in achieving target blood pressure (<140/90 mmHg) over a 6-week period.

Other names

lisinopril + placebo-GlaxoSmithKline-essential hypertensionlisinopril monotherapy